Direct answer. Truncus arteriosus, also called common arterial trunk, is a congenital condition with a single common arterial outlet supplying the body and lungs instead of the usual separate outflows. Associated ventricular and truncal-valve findings matter. Surgery establishes separate routes, but a conduit and other repaired structures can need further attention as a child grows and in adulthood. Confidence is high in these distinctions; no fixed operation age, replacement schedule or independently cleared procedural ranking is supplied. CDC truncus arteriosus and repair context, January2026; AHA truncus arteriosus clinical education, August2026.
- A common trunk is a distinct structural outflow condition.
- A ventricular opening and abnormal truncal valve can add important findings.
- Excess lung flow and mixing are different physiological consequences to assess.
- A conduit does not grow with the child and may later become too small or narrowed.
- Continuing care should consider the conduit, truncal valve, pumping function and rhythm.
Evidence summary
| Question | Source role | Conclusion and confidence |
|---|---|---|
| What is common? | Anatomical education | An arterial outlet supplying the body and lungs. High confidence. |
| Are vessel and valve questions identical? | Structural context | No. The truncal valve can have a separate narrowing or leakage finding. |
| Does a conduit grow normally? | Current society care context | No. Growth and narrowing can create later assessment needs. |
| Is the operation a universal final procedure? | Long-term congenital framework | No. Further findings or interventions may occur. |
Confidence is high in the condition distinctions and need for appropriate assessment. The treatment section attributes clinical guidance; it does not certify the funding of every underlying intervention trial. Independent comparative outcome certainty and a supplement replacement regimen were not established by this focused review. A public institution or independent review cannot make a sponsored original trial financially independent.
What it is
Normally, the aorta supplies the body and the pulmonary artery supplies the lungs through separate outflow routes. In common arterial trunk, a single outlet gives rise to those circulations. It is distinct from transposition, in which separate great arteries connect to different ventricles, and from isolated narrowing of an otherwise formed pulmonary valve. NHLBI congenital anatomy and condition taxonomy, March2022; Evelina London original congenital condition and selected-care education.
A ventricular septal opening is commonly present. The truncal valve controlling the common outlet can also be abnormal, including narrowing or leakage. The clinical assessment should describe the artery, valve and ventricular findings together rather than compress them into one statement that an artery did not separate. CDC truncus arteriosus and repair context, January2026.
How it works
Mixing and the distribution of blood between lungs and body affect oxygen delivery and workload. Excessive pulmonary flow can add strain; the valve can create another burden if it leaks or obstructs outflow. The actual clinical effect needs anatomical and functional assessment, not a prediction from the common-trunk name alone. CDC truncus arteriosus and repair context, January2026.
Persistent excessive lung flow can affect the pulmonary vessels. The current AHA education highlights pulmonary vascular concerns and the importance of early assessment. This does not provide a personal pressure forecast or a claim that every postoperative patient has the same pulmonary-hypertension mechanism. AHA truncus arteriosus clinical education, August2026.
Diagnosis can occur before birth or during evaluation after delivery. Echocardiography describes the structural findings; selected additional investigations answer specific uncertainties. Screening and anatomical diagnosis are different tasks, and a passed newborn oxygen screen cannot exclude every critical congenital defect. A new severely unwell baby still needs prompt care. NHLBI congenital investigation education, March2022; CDC professional critical-heart screening limitations, December2025.
The cause is often unresolved. Wider fetal or genetic assessment can be relevant when there is a defined question about associated findings. A parent should not be assigned blame or a specific genetic diagnosis from a general association. Counselling should explain the actual child’s findings and what a proposed test can establish. NHLBI congenital contributors and unresolved causes, March2022; Evelina London prenatal congenital diagnosis and counselling, December2025.
The evidence-based treatments
Early specialist care addresses the actual circulation and illness. Selected medicines and feeding support can be necessary, but they do not divide the common outlet into an ordinary pair of vessels. General congenital education distinguishes medical support from surgery or selected catheter procedures; the team must explain which problem each component of care addresses. NHLBI congenital procedure background, March2022.
Repair aims to create separate pulmonary and systemic routes, often including a ventricular patch and a right-ventricle-to-pulmonary-artery conduit. The original common trunk contributes to the systemic route. This simplified account is clinical education, not a universal operative instruction: exact anatomy and stability determine the plan. CDC truncus arteriosus and repair context, January2026.
A conduit may become too small as the child grows or develop narrowing. The pulmonary arteries and truncal valve can also require review. Further catheter treatment or surgery may be appropriate for a defined finding. A future procedure is not automatically evidence that initial surgery failed, and an implanted conduit does not establish that every later symptom comes from it. AHA truncus arteriosus clinical education, August2026.
Adult congenital care should interpret current anatomy and function with the original repair details. Rhythm recording addresses suspected electrical findings, while imaging addresses valves, pumping function or reconstructed routes. Medicines and further procedures need an actual indication; a generic adult heart-failure regimen cannot settle every congenital question. AHA original2025 congenital patient messages; NHLBI arrhythmia diagnosis.
The current AHA condition page was actually opened and reviewed August2026. Its institutional pharmaceutical/device support and unresolved contributor/trial chain keep it C-provisional attributed care context. A promise of an excellent outcome or a specific procedure’s superiority is not imported into this guide’s independent verdict. AHA truncus arteriosus clinical education, August2026.
Supplement and lifestyle evidence
Feeding and growth support in infancy should fit the current workload and clinical plan. Later activity should account for present function and any rhythm or valve problem, rather than impose a universal lifetime sports ban. Good dental and wider cardiovascular habits support general health; antibiotic prophylaxis needs an actual indication and local review. Emotional and developmental support can remain relevant after surgery. NHLBI lifelong congenital follow-up, March2022.
No supplement is established here as a treatment for truncus arteriosus. “Heart support,” improved vessel relaxation, a changed blood marker and fewer clinical events are different claims. The cited source set does not provide a fully financially screened trial basis for replacing diagnosis or prescribed care. Correcting a clinician-confirmed deficiency is a separate indication; a retail blend is not a diagnostic test or an emergency treatment.
What works and what does not
Useful common-trunk care separates the initial circulation, the result of repair and the current valve, conduit or lung-vessel question. It explains the purpose of each investigation and what finding would justify another intervention. A completed procedure, an open conduit, improved symptoms and long-term survival are different outcomes. Growth-related review should be explained as part of the evolving circulation rather than a fixed replacement deadline.
Ask which outcome is being pursued: symptoms, physiological findings, recurrence, hospital admission or survival. A plan should also say how adverse effects and deterioration will be recognized. Personal stories and before-and-after readings cannot separate treatment effects from the natural course, other medicines or selection of patients. Manufacturer or materially conflicted outcome claims do not determine this article’s independent verdict.
Risks and side effects
Severe breathlessness, blue/grey or markedly ashen colour, limpness, collapse or reduced responsiveness in a baby or child requires emergency help. Major feeding or breathing deterioration needs prompt assessment. Later collapse, substantial breathing difficulty, severe chest symptoms or abrupt neurological changes should not wait for a congenital appointment. A previously passed screening result or earlier satisfactory operation must not delay help. NHS congenital heart disease national guidance, December2025.
The congenital circulation, pulmonary-vessel burden and abnormal valve findings can be serious. Procedures and medicines also have risks, including bleeding, infection, injury and remaining dysfunction. Later conduit or valve intervention may be necessary. This guide does not establish a personal survival estimate or an independently cleared ranking of conduit materials, implants or operative techniques. NHLBI congenital procedure background, March2022.
Important interactions
Review medicines and supplements together, stating the indication for any rhythm, congestion, pressure or clot-prevention treatment. Conduit or valve history should be shared before other invasive procedures. Pregnancy and contraception planning need the actual current function, pulmonary-vessel findings and medicine list. Do not independently start a blood-thinning supplement or stop an essential prescription because another congenital patient uses a different regimen. NHLBI congenital pregnancy and medicine review, March2022.
Bring prescription medicines, non-prescription products, recreational drugs and supplements to the same medication review. Product names alone may hide several active ingredients. The prescriber or pharmacist should check the exact combination and kidney function, rather than treating “natural” as a safety category. Never add a second person’s rescue medicine or stop an important prescribed medicine because an internet list mentions a possible interaction.
Who needs assessment
Ask for the common-outlet anatomy, truncal valve, associated ventricular opening and present pumping function to be explained clearly. After repair, identify the actual conduit, its route and any remaining findings. Current imaging and selected clinical measurements should answer a defined question. A home heart-rate or pressure result cannot establish that a reconstructed vessel or implanted conduit is adequate. NHLBI congenital investigation education, March2022.
Pregnancy and contraception planning should use the actual anatomy, current function and medicine list. A childhood repair label alone cannot establish present safety. Clinical genetic counselling may be appropriate when the question is defined; an inconclusive or negative result does not settle all congenital risk. NHLBI congenital pregnancy and medicine review, March2022.
Clinician-led use and follow-up
Retain the original operative details, conduit record and remaining valve or vessel findings through transition to adult services. Ask what will be monitored, which symptoms require earlier contact and how the next decision will be made. The current findings determine appropriate review, not a schedule copied from a simplified leaflet. Specialist coordination matters for reproductive planning and other procedures as patients grow. AHA original2025 congenital patient messages.
This guide gives no personal drug, device or supplement dose. The appropriate plan depends on the established diagnosis, current stability, other illnesses and local services. Ask for a written explanation of the treatment purpose, warning signs, review schedule and contact route for side effects. Clinical monitoring and informed consent should accompany any change; study exposures are not prescriptions.
Animal and in-vitro evidence
Animal and cellular studies of heart development can investigate mechanisms and candidate genes. They cannot establish a safe human supplement regimen, prove that a structural defect will close, or select an operation for a child or adult. Models may differ substantially from a person’s congenital anatomy and circulation. No animal or in-vitro result contributes to the independent clinical verdict in this guide.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 23 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
Financial interests include specialist imaging, genomic testing, pediatric and adult congenital services, medicines, occluders, conduits and valve implants. Institutional public funding does not clear individual research sponsors. The actual funding routes and unresolved author/trial chain are shown source by source. Manufacturer or materially conflicted clinical outcomes do not determine this article’s independent verdict.
The condition has no corporate owner. Medicines, diagnostics, devices, procedures and marketed supplements create different revenue incentives. This describes financial interests rather than misconduct. Funding tier evaluates proximity to the subject; A–D credibility assesses transparency, accuracy incentives and remaining uncertainty. An unresolved link stays unresolved, and a provisional public-information label does not clear the trials behind it.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHLBI congenital heart defects overview, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Congenital definition and varied severity. |
| NHLBI congenital contributors and unresolved causes, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Contributors and frequent uncertainty; no attribution of individual parental blame. |
| NHLBI congenital symptom education, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Dated symptom education, not a diagnostic screen. |
| NHLBI congenital investigation education, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Anatomy, rhythm and selected investigation context. |
| NHLBI congenital procedure background, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Dated medicine/procedure background; no universal closure or transplant rule. |
| NHLBI lifelong congenital follow-up, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Age-appropriate long-term care and activity. |
| NHLBI congenital pregnancy and medicine review, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Individual reproductive and medication assessment. |
| NHS congenital heart disease national guidance, December2025 | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 1 public education provisional; not a clearance of original studies. | B provisional. Public-service remit and editorial checks support accuracy; simplification, service priorities and incomplete trial-finance tracing limit inference. Role: December2025 current national condition and emergency education. |
| AHA original2025 congenital patient messages | AHA donations, events, bequests and training revenue; 2024–25 report names BMS, Cytokinetics, Novartis and Stryker institutional support. Direct summary funding and joint guideline author/trial chain unresolved. | United States; AHA National Center, Dallas, Texas. Joint professional guidance is multinational; commercial supporter manufacturing origin not traced. | Tier 2 society with relevant drug/device institutional revenue; author chain unresolved. | C provisional. Actual society summary opened, not the full guideline or author disclosures. Professional expertise supports attributed care context; corporate relationships and untraced original trials preclude independent efficacy clearance. Role: December2025 transition and specialist-care messages, C-provisional clinical context. |
| NHLBI congenital anatomy and condition taxonomy, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Critical congenital taxonomy. |
| CDC truncus arteriosus and repair context, January2026 | CDC/HHS federal budget authority and public transfers in FY2026 operating plan. Separate gift authority permits donations, bequests, in-kind support and CDC Foundation transfers with conflict review. These permitted routes do not prove a private gift financed this page. Named donors, page allocation and author/original-study finances unresolved. | United States; CDC Atlanta, Georgia, federal public-health jurisdiction. Archived surveillance handbook has international partner links; complete partner and backer financial chains not cleared. | Tier 1 public education provisional; gift, donor and full page-specific chain unresolved. | B provisional. Public accountability and explicit source/review dates aid checking; policy priorities, simplification and untraced underlying studies limit independent inference. Role: January2026 common vessel, valve and repair education. |
| Evelina London original congenital condition and selected-care education | Separate Guy’s and St Thomas’ NHS Foundation Trust provider: 2025–26 audited accounts document NHS/ICB commissioners, private/overseas patients, research/training, charitable grants and commercial income. Actual page allocation, named reviewers, commercial research sponsors and underlying-trial finances unresolved. National NHS website sponsorship policy does not clear this separate Trust. | United Kingdom; Evelina London, Guy’s and St Thomas’ NHS Foundation Trust, London, England. Pediatric provider scope; local service rather than worldwide care entitlement. | Tier 2 provider with documented private, commercial and charitable revenue; page/author chain provisional. | B provisional for attributed anatomy and clinical context. Specialist expertise and provider accountability aid checking; incomplete review dating, simplification and untraced research interests remain. The page’s broad claim that preterm PDA typically requires surgery is not adopted. Role: Common arterial trunk and specialist structural-treatment context. |
| AHA truncus arteriosus clinical education, August2026 | AHA donations, events, bequests and training revenue; 2024–25 report names BMS, Cytokinetics, Novartis and Stryker institutional support. Direct summary funding and joint guideline author/trial chain unresolved. | United States; AHA National Center, Dallas, Texas. Joint professional guidance is multinational; commercial supporter manufacturing origin not traced. | Tier 2 society with relevant drug/device institutional revenue; author chain unresolved. | C provisional. Actual condition education reviewed August2026 was opened. Professional expertise and dating aid attributed care context; relevant institution drug/device revenue, unnamed page contributors and underlying-trial financial gaps preclude independent efficacy clearance. General outcome assurances are not adopted. Role: August2026 conduit, valve, lung-vessel and adult-care context, C-provisional. |
| Evelina London prenatal congenital diagnosis and counselling, December2025 | Separate Guy’s and St Thomas’ NHS Foundation Trust provider: 2025–26 audited accounts document NHS/ICB commissioners, private/overseas patients, research/training, charitable grants and commercial income. Actual page allocation, named reviewers, commercial research sponsors and underlying-trial finances unresolved. National NHS website sponsorship policy does not clear this separate Trust. | United Kingdom; Evelina London, Guy’s and St Thomas’ NHS Foundation Trust, London, England. Pediatric provider scope; local service rather than worldwide care entitlement. | Tier 2 provider with documented private, commercial and charitable revenue; page/author chain provisional. | B provisional for attributed anatomy and clinical context. Specialist expertise and provider accountability aid checking; incomplete review dating, simplification and untraced research interests remain. The page’s broad claim that preterm PDA typically requires surgery is not adopted. Role: December2025 counselling and wider fetal assessment. |
| CDC professional critical-heart screening limitations, December2025 | CDC/HHS federal budget authority and public transfers in FY2026 operating plan. Separate gift authority permits donations, bequests, in-kind support and CDC Foundation transfers with conflict review. These permitted routes do not prove a private gift financed this page. Named donors, page allocation and author/original-study finances unresolved. | United States; CDC Atlanta, Georgia, federal public-health jurisdiction. Archived surveillance handbook has international partner links; complete partner and backer financial chains not cleared. | Tier 1 public education provisional; gift, donor and full page-specific chain unresolved. | B provisional. Public accountability and explicit source/review dates aid checking; policy priorities, simplification and untraced underlying studies limit independent inference. Role: December2025 screening limits. |
| NHLBI arrhythmia diagnosis | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Recording a possible postoperative rhythm, not symptom-only diagnosis. |
| NHLBI arrhythmias | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Additional original linked in condition-specific education or follow-up. |
| NHLBI budget | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHLBI Gift Fund | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHS national website funding policy | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 3 editorial and financial self-disclosure. | B provisional. Explicit funding policy; actual individual declarations and implementation not audited. Financial provenance only. |
| AHA2024–25 annual report and named corporate support | AHA donations, events, bequests and training revenue; 2024–25 report names BMS, Cytokinetics, Novartis and Stryker institutional support. Direct summary funding and joint guideline author/trial chain unresolved. | United States; AHA National Center, Dallas, Texas. Joint professional guidance is multinational; commercial supporter manufacturing origin not traced. | Tier 3 institutional financial/contact self-disclosure. | B provisional for named revenue, support and location; C for certifying independence. AHA is financially interested in its own institutional account; direct clinical-page support and all partner-society finances unresolved. Financial provenance only. |
| AHA National Center Dallas contact | AHA donations, events, bequests and training revenue; 2024–25 report names BMS, Cytokinetics, Novartis and Stryker institutional support. Direct summary funding and joint guideline author/trial chain unresolved. | United States; AHA National Center, Dallas, Texas. Joint professional guidance is multinational; commercial supporter manufacturing origin not traced. | Tier 3 institutional financial/contact self-disclosure. | B provisional for named revenue, support and location; C for certifying independence. AHA is financially interested in its own institutional account; direct clinical-page support and all partner-society finances unresolved. Financial provenance only. |
| CDC original FY2026 operating plan | CDC/HHS federal budget authority and public transfers in FY2026 operating plan. Separate gift authority permits donations, bequests, in-kind support and CDC Foundation transfers with conflict review. These permitted routes do not prove a private gift financed this page. Named donors, page allocation and author/original-study finances unresolved. | United States; CDC Atlanta, Georgia, federal public-health jurisdiction. Archived surveillance handbook has international partner links; complete partner and backer financial chains not cleared. | Tier 3 institutional finance, policy or contact self-disclosure. | B provisional for documented finance routes and location. Gift policy is dated2016 with2022 editorial review; actual donors, implementation, page allocations and individual independence not audited. Financial provenance only. |
| CDC dated2016 gift authority,2022 editorial review | CDC/HHS federal budget authority and public transfers in FY2026 operating plan. Separate gift authority permits donations, bequests, in-kind support and CDC Foundation transfers with conflict review. These permitted routes do not prove a private gift financed this page. Named donors, page allocation and author/original-study finances unresolved. | United States; CDC Atlanta, Georgia, federal public-health jurisdiction. Archived surveillance handbook has international partner links; complete partner and backer financial chains not cleared. | Tier 3 institutional finance, policy or contact self-disclosure. | B provisional for documented finance routes and location. Gift policy is dated2016 with2022 editorial review; actual donors, implementation, page allocations and individual independence not audited. Financial provenance only. |
| CDC actual Atlanta contact and public-site provenance | CDC/HHS federal budget authority and public transfers in FY2026 operating plan. Separate gift authority permits donations, bequests, in-kind support and CDC Foundation transfers with conflict review. These permitted routes do not prove a private gift financed this page. Named donors, page allocation and author/original-study finances unresolved. | United States; CDC Atlanta, Georgia, federal public-health jurisdiction. Archived surveillance handbook has international partner links; complete partner and backer financial chains not cleared. | Tier 3 institutional finance, policy or contact self-disclosure. | B provisional for documented finance routes and location. Gift policy is dated2016 with2022 editorial review; actual donors, implementation, page allocations and individual independence not audited. Financial provenance only. |
| Guy’s and St Thomas’ audited2025–26 accounts | Separate Guy’s and St Thomas’ NHS Foundation Trust provider: 2025–26 audited accounts document NHS/ICB commissioners, private/overseas patients, research/training, charitable grants and commercial income. Actual page allocation, named reviewers, commercial research sponsors and underlying-trial finances unresolved. National NHS website sponsorship policy does not clear this separate Trust. | United Kingdom; Evelina London, Guy’s and St Thomas’ NHS Foundation Trust, London, England. Pediatric provider scope; local service rather than worldwide care entitlement. | Tier 3 audited institution financial self-disclosure. | B provisional for revenue provenance. Audited group accounts improve scrutiny but do not identify clinical-page allocations, full donor or individual author independence. Financial provenance only. |
Frequently asked questions
Is common arterial trunk another name for truncus arteriosus? Yes. Both describe the common-outlet condition. Evelina London original congenital condition and selected-care education.
Is the truncal valve a separate follow-up question? Yes. Its narrowing or leakage can matter independently of conduit findings. CDC truncus arteriosus and repair context, January2026.
Will a conduit grow with the child? No. Growth and later narrowing can require further assessment. AHA truncus arteriosus clinical education, August2026.
Does a childhood operation remove adult care needs? No. Continuing congenital follow-up remains important. AHA original2025 congenital patient messages.
Sources and funding notes
- NHLBI congenital heart defects overview, March2022 — Congenital definition and varied severity.
- NHLBI congenital contributors and unresolved causes, March2022 — Contributors and frequent uncertainty; no attribution of individual parental blame.
- NHLBI congenital symptom education, March2022 — Dated symptom education, not a diagnostic screen.
- NHLBI congenital investigation education, March2022 — Anatomy, rhythm and selected investigation context.
- NHLBI congenital procedure background, March2022 — Dated medicine/procedure background; no universal closure or transplant rule.
- NHLBI lifelong congenital follow-up, March2022 — Age-appropriate long-term care and activity.
- NHLBI congenital pregnancy and medicine review, March2022 — Individual reproductive and medication assessment.
- NHS congenital heart disease national guidance, December2025 — December2025 current national condition and emergency education.
- AHA original2025 congenital patient messages — December2025 transition and specialist-care messages, C-provisional clinical context.
- NHLBI congenital anatomy and condition taxonomy, March2022 — Critical congenital taxonomy.
- CDC truncus arteriosus and repair context, January2026 — January2026 common vessel, valve and repair education.
- Evelina London original congenital condition and selected-care education — Common arterial trunk and specialist structural-treatment context.
- AHA truncus arteriosus clinical education, August2026 — August2026 conduit, valve, lung-vessel and adult-care context, C-provisional.
- Evelina London prenatal congenital diagnosis and counselling, December2025 — December2025 counselling and wider fetal assessment.
- CDC professional critical-heart screening limitations, December2025 — December2025 screening limits.
- NHLBI arrhythmia diagnosis — Recording a possible postoperative rhythm, not symptom-only diagnosis.
- NHLBI arrhythmias — Additional original linked in condition-specific education or follow-up.
- NHLBI budget — Financial provenance only.
- NHLBI Gift Fund — Financial provenance only.
- NHS national website funding policy — Financial provenance only.
- AHA2024–25 annual report and named corporate support — Financial provenance only.
- AHA National Center Dallas contact — Financial provenance only.
- CDC original FY2026 operating plan — Financial provenance only.
- CDC dated2016 gift authority,2022 editorial review — Financial provenance only.
- CDC actual Atlanta contact and public-site provenance — Financial provenance only.
- Guy’s and St Thomas’ audited2025–26 accounts — Financial provenance only.
Original clinical pages and their relevant financial disclosures were opened. Actual December2025 AHA adult-congenital summaries and patient messages were read. The full2025 ACC/AHA/HRS/ISACHD/SCAI guideline, author-declaration chain and slide download were blocked and were not read. No complete guideline assessment or numeric intervention criterion is inferred from the summaries. AHA2024–25 institutional financial disclosures and Dallas contact were checked; joint-society finances and direct page allocation remain unresolved. Institutional corporate funding is not assumed to fund this particular document. These summaries are attributed C-provisional clinical context, excluded from the independent efficacy verdict. Guidance, classification, emergency education and independent efficacy are distinct source roles. A full systematic review, complete society donor audit and author-by-author clearance of original treatment trials were not completed.
Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.
